In 2011, amid much controversy and intense discussions on a national and international platforms, the U.S. Preventative Services Task Force concluded that “the potential benefit does not outweigh the harms,” with regard to the use of PSA screening as a means to prevent prostate cancer specific mortalities in men [4]. The gene discussed is KLK3; the disease is prostate carcinoma.